Skip to main content

Table 5 Threshold leves and Corresponding value based price of Sorafenib

From: A pilot study to assess feasibility of value based pricing in Cyprus through pharmacoeconomic modelling and assessment of its operational framework: sorafenib for second line renal cell cancer

Willingness to pay Threshold

20,000

40,000

60,000

>100,00 (102,616)

Cost of sorafenib arm

10620 (CI 95% 9022.0-12490.0)

13760 (CI 95% 11680.0-16290.0)

16996 (CI 95%14370.0-20120.0)

23806 (CI 95% 20,000 -28220)

Cost of bsc arm

7336.0 (CI 95%: 6327.0- 8468.0).

7336.0 (CI 95%: 6327.0- 8468.0).

7336.0 (CI 95%: 6327.0- 8468.0).

7336.0 (CI 95%: 6327.0- 8468.0).

Incremental QALY gains

0,1605 QALY

0,1605 QALY

0,1605 QALY

0,1605 QALY

Incremental cost

3284

6424

9630

16470

VBP of sorafenib

810

1325

1816

2880